Spondy art

ANCA vasculitis awareness day at the VA(?)

After a long day at work, finding my #ACR25 #RheumCat sticker waiting for me brought a smile. Dr. @rheumcat.bsky.social makes Rheumatology easier to navigate through her dedication, motivation, and genuine care for her trainees. Her example inspires me every day, and I am forever grateful. 💙🐈‍⬛

Baby thinking if he should be a #Rheumatologist

Poster: subcutaneous tocilizumab may be more effective in #GCA than IV. So unfortunate that many of our seniors can only get IV due to health insurance 😢 #ACR25

I did comb through our #GCA Fast Track Clinic and also didn’t find seasonal variation but agree, sure feels like it is seasonal at times! #ACR25

Unfortunate information on #ANCA vasculitis and #GCA clinical trials showing poor representation of patients and a low number even reporting race. We need to do better. #ACR25

@uwrheum.bsky.social yay!

Congrats to @renatoferrandiz.bsky.social on the publication of the SPARTAN Clinical Year in Review He transformed the talk that I gave into digestible figures and text rdcu.be/euouC cc @ruthjeannapier.bsky.social @mohamadbittarmd.bsky.social @spondymd.bsky.social @restovall.bsky.social

Our work was cited in terms of diagnostic delay in axial spondyloarthritis @renatoferrandiz.bsky.social @spondymd.bsky.social

Editor's Picks Spotlight Disparities in Time to Diagnosis of Radiographic Axial Spondyloarthritis with Drs. Renato Ferrandiz-Espadin, Jean W. Liew and Maureen Dubreuil @renatoferrandiz.bsky.social @rheumcat.bsky.social @spondymd.bsky.social 📖 doi.org/10.3899/jrhe... 📽️ youtu.be/jXAe-dlbxsc

Editorial Disparities in Diagnosis: A Call for Equity in Radiographic Axial Spondyloarthritis Care 📖 doi.org/10.3899/jrhe... @umasschan.bsky.social #socialdisparities #radiographic #axSpA

Nancy By Ernie Bushmiller April 4,1950

Great days at the #ACP25

Research Article Disparities in Time to Diagnosis of Radiographic Axial Spondyloarthritis 📖 www.jrheum.org/cgi/content/... @renatoferrandiz.bsky.social @rheumcat.bsky.social @spondymd.bsky.social #socialdisparities #radiographic #axSpA

We found that diagnostic delay in axial spondyloarthritis was 21% longer (7 months) among people with a social need, using an accelerated failure time model. @jrheumatol.bsky.social @renatoferrandiz.bsky.social www.jrheum.org/content/52/4...

T3f: #NephJC Obinutuzumab is currently tested as an add-on to lower steroids + high-dose MMF in LN. (Although, has anyone seen some palpable number on cortico total dose) Key question: Can it reduce background immunosuppression?

T3e: And their results: their definitions of CRR, PRR vary #NephJC Any thoughts?

T3d: Here are the trials with cell B blockers (yeah, induction, refractory LN, or whatever). Any notable differences in their design? #nephjc

T3b: Obinutuzumab achieved sustained B-cell depletion (CD19+ <10/µL) in 95% of patients through week 76, outperforming Rituximab (~80% at week 52, LUNAR trial). pubmed.ncbi.nlm.nih.... Obvious question: why REGENCY was positive and LUNAR negative? #nephJC

T3a: Short recap: #NephJC 🔹REGENCY trial confirms type 2 anti-CD20 efficacy in active lupus nephritis. 🔹Obinutuzumab + standard therapy improved renal response vs. placebo, aligning with NOBILITY trial findings

T0l: #NephJC Type II anti-CD20 mAbs (e.g., obinutuzumab) induce stronger B-cell cytotoxicity and enhanced phagocytosis, resulting in deeper and more sustained depletion, including in tissue-resident B-cell niches

T0k: #NephJC Based on BLISS-LN findings, belimumab is recommended by @kdigo.org as 1st line therapy www.nephjc.com/news/...#NephJC

T0b: About 10–25% of patients will develop chronic kidney disease (CKD), and it has been described mortality of 10–20% at 10yrs #NephJC 🔸Studies= heterogeneous 🔸Demographics associated with worse renal outcomes: age (y<40 at the time of LN diagnosis) and Hispanic ethnicity pubmed.ncbi.nlm.nih....#NephJC

T0d: #NephJC A recent #kireports electronic cohort-based study showed that compared with other primary GNs, in LN there is a slightly ⬇️risk of KRT. With LN-CKD 👉 higher risk of 🔸MACE HR 1.63 (95% CI, 1.32–2.02) 🔸all-cause mortality 1.65 (1.31–2.08) www.kireports.org/ar...#NephJC#kireports

Second positive thing: Mentee @renatoferrandiz.bsky.social is being interviewed by a rheumatology journal for the study he led with us on disparities affecting time to diagnosis for individuals living with axial spondyloarthritis Important DEI work, right there

A very controversial case that may lead to a great discussion! Is #Hydralazine that bad? See you at the #ACP in #NOLA. #lupus

Highlighting again the research we've done on disparities and health equity within rheumatology Work led by @renatoferrandiz.bsky.social: www.jrheum.org/content/earl...

Thrilled to begin my Rheumatology fellowship this year, with a focus on tackling and raising awareness of social disparities! Lets start with r-axSpA! #RheumFellowship #AxSpA #HealthEquity

Before the year ends, I am thankful for the opportunity of publishing this work. I will do my best this 2025 as well! @spondymd.bsky.social @rheumcat.bsky.social